Aavant-Garde & TIGEM’s Groundbreaking Research in Science Advances
AAVantgarde Bio, in collaboration with the Telethon Institute of Genetics and Medicine (TIGEM), published preclinical research in Science Advances...
AAVantgarde Bio, in collaboration with the Telethon Institute of Genetics and Medicine (TIGEM), published preclinical research in Science Advances...
Vaxcyte, a clinical-stage vaccine company, will present topline results from its Phase 2 infant study of VAX-24, a 24-valent...
Nanobiotix announced positive Phase 1 data for NBTXR3 (JNJ-1900), a radiotherapy-activated nanoparticle therapy, in patients with locally advanced non-small...
Portage Biotech presented preclinical data for PORT-7 (TT-4), a selective A2B adenosine receptor inhibitor, at the 2025 European Lung...
Crinetics Pharmaceuticals announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for paltusotine to treat...
Sensei Biotherapeutics announced preliminary positive results from the dose expansion portion of its Phase 1/2 trial of solnerstotug, a...
Bristol Myers Squibb (BMS) announced positive topline results from Phase 3 trials of Sotyktu (deucravacitinib) for psoriatic arthritis (PsA)....
Urteste S.A., a Polish company specializing in early cancer detection through urine analysis, plans to start clinical trials for...
Chemomab Therapeutics announced positive 48-week data from the open-label extension (OLE) of its Phase 2 SPRING trial for nebokitug...
Candel Therapeutics announced final survival data from a Phase 2a clinical trial of CAN-2409 in patients with advanced non-small...